PropertyValue
?:definition
  • The unique identifier assigned to the arm of the Molecular Analysis for Therapy Choice (MATCH) phase II clinical trial that is investigating treatment with nivolumab and relatlimab in patients with progressive neoplastic disease following immune checkpoint inhibitor therapies targeting either PD1 (PDCD1) or PD-L1 (CD247) that are LAG3 positive and have mismatch repair deficiency.
?:hasCUIAnnotation
?:hasGeneratedBy
?:type

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/C5419999_NCI>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/C5419999_NCI>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all